Genetic influences on the response to warfarin

Area of Science:

• Pharmacogenomics
• Clinical Pharmacology
• Drug Metabolism

Background:

• Warfarin, an anticoagulant, possesses a narrow therapeutic index with significant interindividual dose variability.
• Current warfarin dosing regimens often fail to account for patient-specific factors influencing anticoagulation response.
• Understanding genetic and environmental influences is crucial for optimizing warfarin therapy.

Purpose of the Study:

• To review recent research on the impact of genetics on warfarin sensitivity and dose requirements.
• To evaluate the clinical utility of individualized warfarin therapy.
• To highlight the role of pharmacogenetics in warfarin dosing.

Main Methods:

• Review of current scientific literature on warfarin pharmacogenomics.
• Analysis of studies investigating genetic polymorphisms (e.g., CYP2C9, VKORC1) and their effect on warfarin dose.
• Examination of environmental and demographic factors influencing warfarin response.

Main Results:

• Single-nucleotide polymorphisms in CYP2C9 and VKORC1 are major contributors to warfarin dose variability.
• Polymorphisms in other genes have minimal impact on warfarin dose requirements.
• Racial, cultural, genetic, and dietary factors explain variations in warfarin dose needs.

Conclusions:

• Individualizing warfarin therapy based on genetic and environmental factors can potentially minimize adverse effects.
• Prospective studies are needed to confirm the safety, cost-effectiveness, and feasibility of genotype-guided warfarin dosing.
• Integrating CYP2C9 and VKORC1 genotypes with environmental data may lead to safer and more effective warfarin initiation.